The association between timing of initiation of adjuvant therapy and the survival of early stage ovarian cancer patients - An analysis of NRG Oncology/Gynecologic Oncology Group trials.
The association between timing of initiation of adjuvant therapy and the survival of early stage ovarian cancer patients - An analysis of NRG Oncology/Gynecologic Oncology Group trials.
复制标题
DOI：
10.1016/j.ygyno.2016.09.015
复制
发表时间：
2016-12
影响因子：
4.7
通讯作者：
Young R
中科院分区：
文献类型：
--
作者：
Chan JK;Java JJ;Fuh K;Monk BJ;Kapp DS;Herzog T;Bell J;Young R
目的：探讨早期卵巢癌患者开始辅助治疗的时机与生存期的关系。数据来自两个妇科肿瘤组试验(方案编号95和157)中接受手术分期和辅助治疗的妇女。采用Kaplan-Meier估计和调整协变量的Cox比例风险模型进行分析。在497例I-II期卵巢上皮癌患者中，手术至开始辅助治疗的中位时间为23天(25-75%：12-33天)。从手术到开始辅助治疗的时间间隔分为三组：2周、2-4周和4周。相应的5年无复发生存率分别为72.8%、73.9%和79.5%(p=0.62)。5年总生存率分别为79.4%、81.9%和82.8%(p=0.51；p=0.33-全局检验)。与2周相比，2-4周和4周的无复发生存风险比分别为0.90(95%CI=0.59-1.37)和0.72(95%CI=0.46-1.13)。年龄、分期、分级和细胞学是影响预后的重要因素。早期上皮性卵巢癌患者开始辅助治疗的时机与生存期无关。
To determine the association between timing of adjuvant therapy initiation and survival of early stage ovarian cancer patients. Data were obtained from women who underwent primary surgical staging followed by adjuvant therapy from two Gynecologic Oncology Group trials (protocols # 95 and 157). Kaplan-Meier estimates and Cox proportional hazards model adjusted for covariates were used for analyses. Of 497 stage I–II epithelial ovarian cancer patients, the median time between surgery and initiation of adjuvant therapy was 23 days (25th–75th%: 12–33 days). The time interval from surgery to initiation of adjuvant therapy was categorized into three groups: <2 weeks, 2–4 weeks, and >4 weeks. The corresponding 5-year recurrence-free survival rates were 72.8%, 73.9%, and 79.5% (p = 0.62). The 5-year overall survival rates were 79.4%, 81.9%, and 82.8%, respectively (p = 0.51; p = 0.33 - global test). As compared to <2 weeks, the hazard ratio for recurrence-free survival was 0.90 (95%CI = 0.59–1.37) for 2–4 weeks and 0.72 (95%CI = 0.46–1.13) for >4 weeks. Age, stage, grade, and cytology were important prognostic factors. Timing of adjuvant therapy initiation was not associated with survival in early stage epithelial ovarian cancer patients.
登录
查看更多内容
影响因子：
4.7
作者：
Monk, Bradley J.;Han, Ernest;Burger, Robert A.
通讯作者：
Burger, Robert A.
影响因子：
1.6
作者：
Pearson, Karl
通讯作者：
Pearson, Karl
影响因子：
4.7
作者：
Bell, Jeffrey;Brady, Mark F.;Spirtos, Nick M.
通讯作者：
Spirtos, Nick M.
影响因子：
3.8
作者：
Rosa, DD;Clamp, A;Jayson, GC
通讯作者：
Jayson, GC
影响因子：
9.7
作者：
Myoung, H;Hong, SD;Kim, MJ
通讯作者：
Kim, MJ